Taro Pharmaceutical (TARO) and Sun Pharmaceutical mutually agree to terminate their merger agreement in which Sun - a 66% owner of Taro - would have paid $39.50 for the rest of the company (Taro closed at $50.55 last night). SA author Retail Investor has covered the saga here and here, and thinks Taro could be a triple. Shares +0.9% premarket.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs